To determine the influence of a positive genetic test for hypertrophic cardiomyopathy (HCM) on clinical outcome.
H ypertrophic cardiomyopathy (HCM) is the most common genetic cardiac disease, characterized by heterogeneous morphologic expression and clinical course. [1] [2] [3] Mutations in genes coding for myofilament contractile proteins of the cardiac sarcomere represent the most common genetic subtype of HCM, with a 30% to 65% prevalence in various cohort studies. [4] [5] [6] [7] [8] Thus, HCM has been repeatedly defined as a disease of the sarcomere. 1, 9 Early reports fostered the notion that genotyping of patients with HCM might prove useful for risk stratification, with particular regard to sudden cardiac death. [10] [11] [12] However, subsequent studies have failed to establish meaningful relationships among individual sarcomere gene mutations, phenotype, and outcome in HCM cohorts. [1] [2] [3] 12, 13 Indeed, virtually all studies aimed at identifying and emphasizing differences among individual myofilament genes associated with HCM have in fact shown vast overlap of clinical and pathophysiologic correlates among subgroups. [1] [2] [3] [10] [11] [12] [13] [14] [15] Remarkably, no attempts have been made to collectively characterize the clinical profile of patients with myofilamentpositive HCM (ie, patients with identifiable sarcomeric mutations) vs myofilament-negative HCM. To address this gap in the data, our study prospectively assessed the clinical features and outcome of unrelated patients from a large, consecutive HCM cohort after comprehensive mutational screening of the 8 myofilament protein genes that currently form the basis of commercially available genetic tests for HCM.
PATIENTS AND METHODS
The study included 203 unrelated index patients with a confirmed clinical diagnosis of HCM, consecutively enrolled at the Azienda Ospedaliera-Universitaria Careggi, in Florence, Italy, and Ospedale San Camillo, in Rome, Italy, since the beginning of a systematic screening program for myofilament gene mutations. 13 Patients were enrolled from January 1, 2002, through December 31, 2003 . The study patients had already been diagnosed as having HCM and were followed up for a median of 4.1 years before genetic screening became available. Of note, 66 patients (33%) had been followed up for more than 10 years before enrollment in the current study. All patients were white and of Italian origin. Mean ± SD age at enrollment was 50±18 years; 73 patients (36%) were female. Maximum left ventricular (LV) thickness ± SD was 23±6 mm, and 59 patients (29%) had resting LV outflow tract obstruction (peak gradient, >30 mm Hg) ( Table 1) . Diagnosis of HCM was based on 2-dimensional echocardiographic identification of a hypertrophied, nondilated left ventricle, in the absence of another cardiac or systemic disease capable of producing the magnitude of ventricular hypertrophy.
1,2 A family history of HCM was actively investigated in all patients in the course of routine 
ECHOCARDIOGRAPHY
We performed echocardiographic studies with commercially available instruments. We assessed LV hypertrophy with 2-dimensional echocardiography, identifying the site of maximal wall thickness. We considered a peak instantaneous outflow gradient of 30 mm Hg or more, estimated with continuous wave Doppler echocardiography under basal conditions, to be indicative of LV outflow obstruction. 1 We measured LV ejection fraction using the biplane Simpson rule and assessed LV filling pattern by pulse-wave Doppler study at the mitral tip level.
MUTATIONAL ANALYSIS
DNA Extraction and Polymerase Chain Reaction. After informed consent was obtained, genomic DNA was extracted from peripheral blood according to QIAamp DNA Blood BioRobot MDx kit (QIAGEN GmbH, Hilden, Germany). In vitro amplification of all candidate exons was performed by polymerase chain reaction using primers described previously. 13 Abnormal DHPLC elution profiles were sequenced on automated dye terminator cycle sequencing using an ABI Prism 3100 Genetic Analyzer (Applied Biosystems, Foster City, KS). Every mutation identified was confirmed by a new polymerase chain reaction, and, when possible, by restriction enzyme digestion. Novel mutations were considered as disease-causing only if they were absent in 300 unrelated chromosomes from adult, ethnically matched healthy control participants and they produced a change in a highly conserved residue among species and isoforms. Cosegregation of the mutation with the disease was sought in the probands' families. All patients and relatives received pretest and post-test genetic counseling.
FOLLOW-UP PROTOCOL
The follow-up protocol and chosen end points for the study cohort were the same used for the overall HCM population, as previously described. 19 Patients were followed up at yearly intervals or more often if required, with clinical and echocardiographic examination, 12-lead electrocardiography, and 24-to 48-hour ambulatory electrocardiography.
STUDY END POINTS
The first clinical end point was cardiovascular death, including death related to heart failure, myocardial infarction, or stroke; sudden unexpected death, including resuscitated cardiac arrest; and postoperative death after cardiac surgery. This end point also proved equivalent to all-cause mortality, as no noncardiovascular deaths occurred. The second clinical end point was unfavorable outcome, a combined end point including cardiovascular death, nonfatal stroke, or progression to severe functional limitation (New York Heart Association [NYHA] class III or IV) at final evaluation.
Echocardiographic end points used in this study were systolic dysfunction, defined as an LV ejection fraction less than 50% at final evaluation; and a restrictive LV filling pattern, considered evidence of severe diastolic dysfunction and defined by a mitral ratio of peak early to late diastolic filling velocity (E/A ratio) of 2 or more in conjunction with deceleration time of 150 ms or less or, in patients with atrial fibrillation, by a transmitral deceleration time of less than 120 ms.
20,21
STATISTICAL ANALYSES Unpaired t test was used for the comparison of normally distributed data. The χ 2 or Fisher exact test was used to compare noncontinuous variables expressed as proportions. Hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated using univariate and multivariate Cox proportional hazard regression models. Multivariate analysis was performed with a stepwise forward regression model, in which each variable with P<.05 (based on univariate analysis) was entered into the model. Survival curves were constructed according to the Kaplan-Meier method, and comparisons were performed using the logrank test. Time of genetic testing was considered as time 0 for clinical end points. However, to assess the lifelong occurrence of LV dysfunction with respect to myofilament mutation status, age was used as the time scale in assessing echocardiographic end points. 22 Patients with multiple mutations counted as single individuals in all analyses. P values are 2-sided and considered significant when <.05. Calculations were performed using SPSS 12.0 software (SPSS, Chicago, IL).
RESULTS

COMPREHENSIVE MUTATIONAL ANALYSIS
In 126 (62%) of the 203 study patients, we identified 87 distinct mutations, of which 51 were classified as novel ( Figure 1 , Table 2 ). These 126 patients were considered to have myofilament-positive HCM. The remaining 77 patients (38%) had no discernible myofilament mutations and were considered to have myofilament-negative HCM. The most frequent disease-associated gene was MYBPC3 (n=68; 34%; including 9 patients with double mutations in this gene). The MYBPC3 E258K mutation, which was found in 27 index patients, suggested a founder effect and was associated with heterogeneous cardiac morphology and clinical presentation. Among the other patients, 41 (20%) had mutations in thick-filament protein genes (34 in MYH7 and 7 in MYL2) and 11 (5%) in thinfilament protein genes (7 in TNNT2, 2 in TPM1, 1 in TNNI3, and 1 in ACTC). Six patients (3%) were double heterozygous (ie, carried mutations in 2 different genes; Table  2 ).
Morphologic features of patients with myofilamentpositive or myofilament-negative HCM were indistinguishable on the basis of clinical, instrumental, and postoperative histologic findings. Age at the time of genetic testing, sex, NYHA functional class, maximum LV wall thickness, and prevalence of resting LV outflow tract obstruction were comparable in patients with myofilamentpositive and myofilament-negative HCM. The overall prevalence of atrial fibrillation was not significantly different in the 2 groups, although the chronic form of the arrhythmia was more prevalent in the myofilament-positive patients. Follow-up duration and referral rates for septal myectomy, alcohol septal ablation, or implantation of a cardioverter-defibrillator were similar. However, patients with myofilament-positive HCM more often had family history of HCM and sudden cardiac death (Table 1) .
CLINICAL COURSE AND OUTCOME Median follow-up after genetic screening was 4.5 years, for a total of 817 patient-years. During follow-up, 14 patients (7%) died from cardiovascular causes (2 suddenly, 8 owing to heart failure, and 4 owing to other causes, including postoperative complications of surgical myectomy [n=2], myocardial infarction, and stroke). In addition, 20 patients (10%) progressed to NYHA functional class III or IV, and 2 had a cardioembolic stroke. Overall, an unfavorable outcome occurred in 36 patients (18%); 1-, 3-, and 5-year Kaplan-Meier cumulative event rate estimates Frameshift/ter 1 a del = deletion; E = exon; fs = frameshift; ins = insertion; IVS = intervening sequences; ter = stop codon. b Of the 87 mutations identified in our study, 51 were novel. Of these 51, most (33) were confirmed by cosegregation. The remaining 18, for which family studies could not be performed, were considered as disease-causing because they were absent in 300 unrelated chromosomes from adult, ethnically matched healthy controls and produced a change in a highly conserved residue among species and isoforms. For a more complete description of methodology, see reference 18. c Nine patients carried a double MYBPC3 mutation and were included among patients with MYBPC3-associated disease for survival analyses (A522T and V771M; E334K and R470W; IVS18+1c>t and A392fs; R502Q and G490R; T1184N and L1187R; G1206V and E240D; A693S and D786Y; E258K and P910T; E258K and E441K for the whole cohort were 2%, 11%, and 16%, respectively (Table 1) .
Among patients with myofilament-positive HCM, 1-, 3-, and 5-year rates for unfavorable outcome were 3%, 14%, and 22%, respectively. The combined end point occurred at ages ranging from 14 to 86 years (mean ± SD, 61±18 years; 7 of the 31 patients were younger than 50 years). There was no difference in outcome based on the affected myofilament (MYBPC3, thick or thin; overall, P=.45). Among patients with myofilament-negative HCM, 1-, 3-, and 5-year rates for unfavorable outcome were 0%, 6%, and 8%, respectively, and the end point occurred at ages ranging from 65 to 84 years (mean ± SD, 77±8 years). Difference in outcome between patients with myofilamentpositive vs myofilament-negative HCM was highly significant (P=.002; Figure 2 ) and remained so even after adjusting for the potential MYBPC3 founder effect by including only the first enrolled patient with the E258K mutation in the analysis (P=.003). Adjustment for other shared mutations did not change the final result (eg, for MYH7 R869H; P=.005). In a multivariate model, myofilament-positive HCM was associated with unfavorable outcome; the association was independent of age, NYHA functional class, resting LV outflow obstruction, and atrial fibrillation (HR, 4.27; P=.008, Table 3 ).
With regard to the specific end point of cardiovascular death, the difference between patients with myofilamentpositive and myofilament-negative HCM was not statistically significant (5-year cumulative event rate, 8% vs 5%; P=. 19) . Nevertheless, myofilament-positive HCM accounted for 11 of the 14 cardiovascular deaths, including both sudden deaths and 6 of 8 due to heart failure ( Table  1 ). All 3 cardioembolic strokes (1 fatal and 2 nonfatal) occurred in the myofilament-positive group.
PREVALENCE OF LV DYSFUNCTION
At final echocardiographic evaluation, 50 patients (25%) had severe LV impairment, including 22 with systolic dysfunction (ie, end-stage phase) and 28 with restrictive filling pattern (Table 1) . Cumulative rates of LV impairment at 1, 3, and 5 years were 4%, 7% and 17%, respectively. Of the 22 patients with systolic dysfunction, 18 (82%) had myofilament-positive HCM owing to mutations in MYBPC3 (n=13), MYH7 (n=2), MYL2 (n=1), TPM1 (n=1), and in a MYBPC3 and MYH7 double heterozygote. Of note, systolic impairment was common among the 27 probands with the MYBPC3 E258K mutation (n=9; 33%). Conversely, only 4 patients (18%) with severe systolic dysfunction had myofilament-negative HCM. Patients with severe LV impairment included 22 (61%) of the 36 patients with an unfavorable outcome.
Patients with myofilament-positive HCM showed greater probability of severe LV systolic and/or diastolic dysfunction than those with myofilament-negative HCM (HR, 2.1; 95% CI, 1.1-4.0; P=.02; Figure 3 ). No significant difference was found on the basis of the affected myofilament (MYBPC3, thick or thin); although double heterozygous patients appeared to be at higher risk ( Figure  3) . These results were unchanged after adjustment for the potential MYBPC3 E258K founder effect (HR for development of systolic and/or diastolic dysfunction, 2.1; 95% CI, 1.1-4.2; P=.02).
DISCUSSION
Our study shows that the identification of 1 or more cardiac myofilament gene mutations is associated with increased risk of LV dysfunction and adverse outcome due to heart failure in patients with HCM. In our cohort, myofilamentpositive HCM was characterized by an almost 30% prevalence of severe systolic and/or diastolic LV dysfunction, which was increasingly common after the fourth decade of life and occurred at a similar rate for each of the 3 major myofilament subtypes involved. By comparison, myofilament-negative HCM was associated with later onset and an approximately 50% lower risk of LV impairment. In an average of 4 years after genetic testing, the difference in prevalence of LV dysfunction in patients with myofilament-positive vs myofilament-negative HCM was reflected in a more severe outcome in the former, mostly due to heart failure. In the myofilament-positive HCM group, 25% of patients experienced an unfavorable outcome (defined as the combination of cardiovascular death, nonfatal stroke, or progression to NYHA classes III or IV), occurring in all age groups including young adults and adolescents. Conversely, only 7% of patients with myofilament-negative HCM reached the same end point, and all of these patients were 65 years or older. Such difference in outcome, which was evident despite virtually indistinguishable clinical features and risk profile at the time of genetic testing, proved highly significant (P=.002). In a multivariate model, which included established predictors of risk for HCM such as NYHA functional class, resting LV outflow obstruction, and atrial fibrillation, the presence of any myofilament gene mutation was associated with a more than 4-fold independent increase in risk of an unfavorable outcome when compared with patients with HCM who had negative results on genetic testing. Our findings suggest that myofilament-positive HCM is frequently characterized by progressive impairment of LV diastolic and systolic function, 23 leading to clinical deterioration and heart-failure-related complications, including atrial fibrillation and stroke, in a sizeable proportion of patients. 19, 22, 24 Specifically, most (82%) of the 22 patients with LV systolic dysfunction at last evaluation (ie, the end-stage phase) had myofilament-positive HCM, caused by mutations in 4 different genes (MYBPC3, MYH7, MYL2, TPM1). Systolic dysfunction was particularly common in a subset of 27 unrelated index patients sharing the MYBPC3 E258K mutation, likely because of a founder effect. Such observations are in close agreement with the recent report by Kubo et al, 22 showing progressive LV remodeling and adverse outcome in patients with a founder-effect, frameshift/deletion mutation in MYBPC3. Thus, although the end-stage phase does not appear to be confined to any specific genetic substrate within the sarcomere, a preferential role in promoting systolic dysfunction may be hypothesized for MYBPC3-encoded myosinbinding protein C. 22, 25 Overall, our observations support a clinical role for systematic genetic testing in the index patient with HCM and have potential implications for management. Specifically, the greater risk of heart failure-related compli- Survival free of systolic dysfunction (%) FIGURE 3. Cumulative occurrence of left ventricular (LV) dysfunction in relation to individual age and myofilament genetic status. Patients were censored at the age of first documentation of LV dysfunction, as defined for each panel. A, Survival free of systolic dysfunction, defined as LV ejection fraction <50%; B, Survival free of restrictive LV filling pattern, defined as transmitral deceleration time <120 ms or a mitral ratio of peak early to late diastolic filling velocity (E/A ratio) of ≥2 in conjunction with a deceleration time of ≤150 ms; C, Survival free of both systolic dysfunction and restrictive LV filling (whichever occurred first).
cations may warrant closer follow-up in patients with myofilament-positive HCM to promptly detect LV dysfunction; manage treatable features, such as atrial fibrillation, outflow tract obstruction, and comorbidity; and anticipate changes in clinical course. 24, 26 In contrast, the identification of patients with myofilament-negative HCM is likely to lead to more in-depth clinical and genetic work-up exploring rare conditions causing (or mimicking) HCM. 2, 27, 28 The processes leading from single-gene mutations to development of clinically recognized HCM, and from phenotypic expression of a generally hyperdynamic LV to functional impairment, are still largely unknown. 23 Hypotheses that mutant sarcomere myofilament proteins depress contractile function, leading to activation of the signaling pathways for compensatory hypertrophy, 29 are inconsistent with recent evidence of gain of function of HCM-related mutant myosins. 30 Pilot mechanical experiments in human cardiac myofibrils also indicate that the kinetics of specific steps of the force-generating adenosine triphosphatase reaction are faster in the sarcomeres of patients with HCM who carry MYBPC3 or MYH7 mutations, leading to increased energy consumption, than in sarcomeres of control patients. 31 From a pathophysiologic standpoint, marked impairment in whole-heart energetics associated with mutations of several sarcomeric proteins in patients with HCM 32 and in animal models 33, 34 suggest that increased energy cost of cardiac function may be a common feature of several HCM-susceptibility genes. 35 Our findings support the idea that similar maladaptive mechanisms, triggered by inefficient sarcomere energy use, may occur in myofilamentpositive HCM, irrespective of the gene involved, leading progressively to LV impairment. 23 As a consequence, the site of individual sarcomere gene mutations would not qualitatively affect the pathophysiologic mechanisms involved so much as it would determine the process quantitatively. 36 This concept is further supported by the finding that double heterozygous patients with HCM showed greater and earlier LV impairment, likely reflecting a more profound derangement of sarcomeric protein function. 37 We are aware that to consider all patients with myofilament-negative HCM as a single group is an unavoidable oversimplification of our current study and that further research in this area is needed. Myofilament-negative HCM is thought to be a composite entity, probably comprising a multitude of rare, heterogeneous, and yet-to-beidentified HCM-susceptibility genes, including rare highrisk subsets. 2, 27 We also acknowledge the likelihood that a proportion of patients currently classified as myofilamentnegative may nevertheless have HCM-susceptibility mutations in novel myofilament-encoding genes or in unexplored regions (eg, promoters, introns) of the known HCMassociated myofilament genes. In clinical practice, each patient with such mutations deserves in-depth individual assessment until the entire molecular and clinical spectrum of HCM is unraveled.
23,38
The quest for novel disease-causing genes in HCM is ongoing. Currently, efforts are moving along 2 main pathways. The first addresses genes coding for Z-disk proteins, which are essential for the structural organization of the cardiac sarcomere and the cardiomyocyte's stretch sensor. These include titin (TTN), muscle LIM protein (CSRP3), telethonin (TCAP), and myozenin 2 (MYOZ2). 38 Recently, an HCM case associated with a mutation in the vinculin gene was reported. 39 Vinculin is a cytoskeletal protein localized to intercalated disks and functions as an actininteracting protein that anchors the thin filaments to the intercalated disks. The second pathway follows the description of mutations in the γ2 subunit of adenosine monophosphate-dependent protein kinase (PRKAG2) and in the lysosomal-associated membrane protein 2 (LAMP2), which cause unexplained hypertrophy resembling HCM. 27, 28 These findings suggest a link between such entities and storage syndromes such as Fabry disease. 38 The rate of unfavorable outcome in our cohort of patients with HCM was relatively high (16% at 5 years), compared with prior reports that were largely based on patients with newly diagnosed disease. 19, 26 However, patients in the current study already had a substantial history of disease at the time of enrollment, including approximately one-third (66; 33%) with a clinical diagnosis dating back more than 10 years. We think such clinical background largely accounts for the seemingly higher rate of diseaserelated complications.
CONCLUSION
Hypertrophic cardiomyopathy due to myofilament gene mutations is characterized by adverse outcome and more frequent derangement of LV function compared with myofilament-negative disease, irrespective of the myofilament type involved. These findings support a clinical and prognostic role for genetic testing in patients with clinically diagnosed HCM.
